ArticleBMC cancer2013
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Genetic and Epigenetic Biomarkers Associated with Early Relapse in Pediatric Acute Lymphoblastic Leukemia: A Focused Bioinformatics Study on DNA-Repair Genes.Biomedicines · 2024Article
- The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.Diagnostics (Basel, Switzerland) · 2021Article
- Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent.Frontiers in oncology · 2021Review
- The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.Pathology oncology research : POR · 2020Article
- PARP1 is a versatile factor in the regulation of mRNA stability and decay.Scientific reports · 2019Article
- Article
- Regulatory network involving miRNAs and genes in serous ovarian carcinoma.Oncology letters · 2017Article
- Trial watch - inhibiting PARP enzymes for anticancer therapy.Molecular & cellular oncology · 2016Review
- A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.Scientific reports · 2014Article
- BRCA1 regulates insulin-like growth factor 1 receptor levels in ovarian cancer.Oncology letters · 2014Article
- Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.BMC cancer · 2014Article
- Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation.Molecular cancer · 2014Article
- Article
- A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.Cell cycle (Georgetown, Tex.) · 2014Article
- Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1.Journal of ovarian research · 2013Article
- Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly (ADP-ribose) polymerase 1 (PARP1) overexpression plays a critical role in ovarian cancer progression and the clinical development of PARP1 inhibitors to treat BRCA-mutated ovarian cancer has advanced rapidly. However, the mechanism regulating PARP1 expression remains unknown. Alterations in gene expression mediated by promoter methylation are being increasingly recognized and have frequently been reported in ovarian cancer. We therefore investigated the methylation status of the PARP1 promoter region and its correlation with PARP1 expression in BRCA-mutated ovarian cancer.
methodsDNA from BRCA-mutated serous ovarian cancer samples and adjacent normal ovarian tissues were analyzed by bisulfite sequence using primers focusing on the CpG island in the promoter region of PARP1. Expression levels of PARP1 were assessed by immunohistochemistry and real-time PCR.
resultsSerous ovarian cancer tissues displayed decreased DNA methylation in the promoter region of PARP1 compared to normal tissue, and methylation intensity correlated inversely with PARP1 mRNA levels. More importantly, E26 transformation-specific (ETS) defined CpG sites were significantly less methylated in ovarian cancer samples.
conclusionsThese results indicate that hypomethylation of the promoter region, especially around the ETS motif might play a role in the upregulation of PARP1 expression in the progression of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.